Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 0.50 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.50 |
| ▸ | CHRNB1 | P11230 | 4/20 | 0.50 |
| ▸ | CHRNB3 | Q05901 | 4/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | SCN1A | P35498 | 1/20 | 0.38 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.38 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | PRKACA | P17612 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1349020 | 1.00 | CHRNB2 (0.50) | CHRNB2CHRNB4CHRNA3CHRNB1CHRNB3 | |
| SCHEMBL6229240 | 0.93 | CHRNB2 (0.45) | CHRNB2CHRNB4CHRNA3CHRNB1CHRNB3 | |
| SCHEMBL1349928 | 0.87 | CHRNB2 (0.48) | CHRNB2CHRNB4CHRNA3CHRNB1CHRNB3 | |
| SCHEMBL1349931 | 0.87 | CHRNB2 (0.48) | CHRNB2CHRNB4CHRNA3CHRNB1CHRNB3 | |
| SCHEMBL1347306 | 0.86 | CHRNB2 (0.52) | CHRNB2CHRNB4CHRNA3CHRNB1CHRNB3 | |
| SCHEMBL1347312 | 0.86 | CHRNB2 (0.52) | CHRNB2CHRNB4CHRNA3CHRNB1CHRNB3 | |
| SCHEMBL1347308 | 0.86 | CHRNB2 (0.52) | CHRNB2CHRNB4CHRNA3CHRNB1CHRNB3 | |
| SCHEMBL1347304 | 0.86 | CHRNB2 (0.52) | CHRNB2CHRNB4CHRNA3CHRNB1CHRNB3 | |
| SCHEMBL4752858 | 0.83 | CHRNB2 (0.42) | CHRNB2CHRNB4CHRNA3CHRNB1CHRNB3 | |
| SCHEMBL4752857 | 0.83 | CHRNB2 (0.42) | CHRNB2CHRNB4CHRNA3CHRNB1CHRNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4663627-B2 | — | — | 2011-04-06 | — | — | JP | claimed |
| JP-2006519868-A | — | — | 2006-08-31 | — | — | JP | claimed |
| EP-1601670-A1 | ARYLVINYLAZACYCLOALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | Targacept Inc. (US) | 2005-12-07 | — | — | EP | claimed |
| WO-2004078752-A1 | ARYLVINYLAZACYCLOALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TARGACEPT INC. (US) | 2004-09-16 | — | — | WO | claimed |
| US-20040176348-A1 | Arylvinylazacycloalkane compounds and methods of preparation and use thereof | AVENTIS PHARMA S.A. | 2004-09-09 | — | — | US | claimed |
| US-20150164894-A1 | ARYLVINYLAZACYCLOALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TARGACEPT, INC. | 2015-06-18 | — | — | US | disclosed |
| US-20140107164-A1 | ARYLVINYLAZACYCLOALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TARGACEPT, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8633222-B2 | Arylvinylazacycloalkane compounds and methods of preparation and use thereof | TARGACEPT, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| CN-101550132-B | Arylvinylazacycloalkane compounds and methods of preparation and use thereof | TARGACEPT INC | 2012-03-28 | — | — | CN | disclosed |
| US-8067443-B2 | Arylvinylazacycloalkane compounds and methods of preparation and use thereof | TARGACEPT, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-8063068-B2 | Arylvinylazacycloalkane compounds and methods of preparation and use thereof | TARGACEPT, INC. (US) | 2011-11-22 | — | — | US | disclosed |
| EP-1947100-B1 | Arylvinylazacycloalkane compounds and methods of preparation and use thereof | TARGACEPT INC (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20100267776-A1 | ARYLVINYLAZACYCLOALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TARGACEPT, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-7714001-B2 | Arylvinylazacycloalkane compounds and methods of preparation and use thereof | TARGACEPT, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100010042-A1 | ARYLVINYLAZACYCLOALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TARGACEPT, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| EP-2085395-A1 | Arylvinylazacycloalkane compounds and methods of preparation and use thereof | Targacept, Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20080293778-A1 | Arylvinylazacycloalkane Compounds and Methods of Preparation and Use Thereof | TARGACEPT, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| EP-1947100-A1 | Arylvinylazacycloalkane compounds and methods of preparation and use thereof | Targacept, Inc. (US) | 2008-07-23 | — | — | EP | disclosed |
| US-7098331-B2 | Arylvinylazacycloalkane compounds and methods of preparation and use thereof | TARGACEPT, INC. (US) | 2006-08-29 | — | — | US | disclosed |
| US-20040176348-A1 | Arylvinylazacycloalkane compounds and methods of preparation and use thereof | AVENTIS PHARMA S.A. | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176348-A1 | Arylvinylazacycloalkane compounds and methods of preparation and use thereof | CHRNA5, OPRK1, CHRNA6 | CHRNB2 7/4885CHRNB4 15/4885CHRNA3 9/4885 |
| US-20140107164-A1 | ARYLVINYLAZACYCLOALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | CHRNA5, OPRK1, CHRNA6 | CHRNB2 7/4885CHRNB4 15/4885CHRNA3 9/4885 |
| US-20100010042-A1 | ARYLVINYLAZACYCLOALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | CHRNA5, OPRK1, CHRNA6 | CHRNB2 7/4885CHRNB4 15/4885CHRNA3 9/4885 |
| US-20080293778-A1 | Arylvinylazacycloalkane Compounds and Methods of Preparation and Use Thereof | CHRNA5, OPRK1, CHRNA6 | CHRNB2 7/4885CHRNB4 15/4885CHRNA3 9/4885 |
| US-20150164894-A1 | ARYLVINYLAZACYCLOALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | CHRNA5, OPRK1, CHRNA6 | CHRNB2 7/4885CHRNB4 15/4885CHRNA3 9/4885 |
| US-20100267776-A1 | ARYLVINYLAZACYCLOALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | CHRNA5, OPRK1, CHRNA6 | CHRNB2 7/4885CHRNB4 15/4885CHRNA3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.